Overseas revenue rose 61.8%, driving performance
"Achieve both quantitative expansion and qualitative improvement"

FineMedix said on the 16th that its consolidated revenue for the first nine months of this year totaled KRW 8.882 billion, up 35.5% from the same period last year.


The company turned a loss of KRW 2.449 billion in the same period last year into a profit of KRW 94 million this year. Its net loss also narrowed to KRW 10 million from KRW 2.25 billion in the same period last year.

FineMedix's 9-Month Revenue Rises 36% to KRW 8.9 Billion View original image

Overseas revenue for the first nine months rose 61.8% year over year to KRW 2.156 billion. The company said sales rose sharply as demand for high-value-added products increased in key markets, including Russia, the United Kingdom and Germany, and that it generated new revenue from multiple sources in Brazil, Chile and Kazakhstan.


Domestic revenue also increased 27% year over year to KRW 6.384 billion. Sales of high-value-added medical instruments, including the ClearCut Knife and ClearTip, grew at major hospitals in the Seoul metropolitan area, driving domestic revenue growth. By product, cumulative sales of ClearTip surged 467%, the strongest growth. Sales of the ClearCut Knife and Snare, the company's existing flagship products, also rose 16% and 14%, respectively, over the same period.



FineMedix CEO Jeon Seongwoo said, "Going forward, I will focus on steadily increasing operating profit alongside expanding revenue. We will grow repeat orders from existing customers in key overseas markets and increase the market share of each product. We will also faithfully carry out plans announced to enhance shareholder value, including share buybacks."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing